Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-04-27

FDA Approved: EPCLUSA — Supplemental Application (Gilead Sciences, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Epclusa (velpatasvir/sofosbuvir) from Gilead Sciences, which expands the established use of the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Epclusa (sofosbuvir/velpatasvir)

Snippet

SUPPL AP for EPCLUSA (VELPATASVIR AND SOFOSBUVIR)